ly03020
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2024 (NCT06556966)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
HTR2C agonist
TAAR5 agonist
TAAR1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07230652 | Phase 1 | Aug 20, 2025 | Luye Pharma |
| NCT07292233 | Phase 1 | Jul 30, 2025 | Luye Pharma |
| NCT06556966 | Phase 1 | Aug 31, 2024 | Capital Medical University, Luye Pharma |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Luye Pharma | For profit | 3 | 3 | 1 | 2024 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1